Table 9. Comparison of HRs for overall survival associated with conventional treatments (based on prior literature), and with cancer-specific survival associated with marriage (in the present study) in AML patients.
| Type of Treatment Study | Chemotherapy or Hematopoietic stem cell transplantation | Reference | HR for Treatment (95% CI) | HR for Marriage in Present Study |
|---|---|---|---|---|
| Meta-Analysis of Prospective Studies [45] | Allogeneic HSCT | Non-allogeneic HSCT (autologous HSCT or chemotherapy | 0.76 (0.61-0.95) | 0.802 (0.782-0.822) |
| Meta-Analysis of Prospective Clinical Trials [46] | High doses of daunorubicin | Standard doses of daunorubicin or idarubicin | 0.88 (0.79-0.99) | |
| Systematic Review and Meta-analysis [47] | High dose of cytarabine | Allogeneic HSCT or autologous HSCT | 1.66 (1.30-2.14) | |
| Meta-analysis of Prospective Randomized Phase III Trials [48] | Gemtuzumab ozogamicin included regimens | Non Gemtuzumab ozogamicin included regimens | 0.93 (0.86-1.00) | |
| Systematic Review and Meta-analysis [49] | Conventional chemotherapy with Gemtuzumab ozogamicin | Conventional chemotherapy alone | 0.95 (0.83-1.08) | |
| Meta-analysis of Randomized Clinical Trials [50] | Idarubicin with cytarabine | Daunorubicin with cytarabine | 0.88 ( 0.81-0.95) | |
| Meta-analysis of Randomized Trials [51] | Autologous HSCT | Non- autologous HSCT | 1.05 (0.91-1.21) | |
| Systematic Review and Meta-analysis [52] | Allogeneic HSCT | Intensive or less intensive chemotherapy | 0.58 (0.51-0.64) | |
| Meta-Analysis of Retrospective Studies [53] | Allogeneic HSCT with reduced-intensity conditioning | Allogeneic HSCT with myeloablative conditioning | 0.97 (0.88-1.07) |
Abbreviation: HSCT, hematopoietic stem cell transplantation; HR, hazard ratio; CI, confidence interval.